Heart failure & cardiomyopathiesRandomised controlled trial
Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)
- Randomised controlled trial
- prospective
- multicentre
- unblinded
Authors' conclusion
A HF screening strategy identified a large proportion of patients living with diabetes with unrecognized symptomatic HF (mostly HF with preserved ejection fraction).
Study context
- Population
- Community-based adults aged ≥40 years with type 1 or type 2 DM and ≥1 additional heart failure (HF) risk factor, without known HF, west of Scotland
- Participants
- 706 adults
- Comparison
- NT-proBNP-based HF screening vs usual care
- Screeningn = 354
- Usual caren = 352reference
- Primary endpoint
- HF diagnosis (2021 ESC HF guidelines definition)
- Follow-up
- 6 months
Primary result
HF diagnosis
Odds ratio
58
95% CI 14–236
P < 0.001
Events by treatment group
Screening vs Usual care
OR 58 (95% CI 14–236); P < 0.001
As reported in the abstract
- Number needed to screen
- 5 (95% CI: 4-6)
Further findings
Median
| Outcome | Unrecognized HF | No HF |
|---|---|---|
| KCCQ-12 overall summary score, unrecognized HF vs no HF | 65.6 | 89.6 |
HF phenotype
- Most cases HF with preserved EF
- 23%
SGLT2 inhibitor use, screening group
- Increased from 24% to 39% in the screening group
KCCQ-12 overall summary score, unrecognized HF vs no HF
- Significantly impaired health status with unrecognized HF
Original publication
Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF). J Am Coll Cardiol. Published 11 August 2026. doi:10.1016/j.jacc.2026.06.042
Summarised from the published abstract; every number is checked against it